Evolus Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Evolus stock.
View analyst ratings for Evolus or view top-rated stocks.

6 Wall Street research analysts have issued 12-month target prices for Evolus' shares. Their EOLS stock forecasts range from $10.00 to $20.00. On average, they expect Evolus' share price to reach $15.33 in the next twelve months. This suggests a possible upside of 31.6% from the stock's current price.
View analysts' price targets for Evolus or view top-rated stocks among Wall Street analysts.

Evolus' stock was trading at $6.51 on January 1st, 2022. Since then, EOLS stock has increased by 79.0% and is now trading at $11.65.
View the best growth stocks for 2022 here.

Evolus is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Evolus.

Evolus, Inc. (NASDAQ:EOLS) announced its quarterly earnings data on Tuesday, May, 10th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.24. The business had revenue of $33.90 million for the quarter, compared to the consensus estimate of $29.83 million. Evolus had a negative net margin of 58.28% and a negative trailing twelve-month return on equity of 80.20%. The firm's revenue was up 177.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.16 earnings per share.
View Evolus' earnings history.

Evolus issued an update on its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $150.00 million-$150.00 million, compared to the consensus revenue estimate of $148.47 million.

1 employees have rated Evolus CEO David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among Evolus' employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Evolus include CureVac (CVAC), Insmed (INSM), ACADIA Pharmaceuticals (ACAD), Arvinas (ARVN), HUTCHMED (HCM), EQRx (EQRX), Global Blood Therapeutics (GBT), Schrödinger (SDGR), Sage Therapeutics (SAGE), ChemoCentryx (CCXI), Ironwood Pharmaceuticals (IRWD), OPKO Health (OPK), Arcus Biosciences (RCUS), Amphastar Pharmaceuticals (AMPH) and Lyell Immunopharma (LYEL).
View all of EOLS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), OrganiGram (OGI) and Bionano Genomics (BNGO).

(EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Evolus' stock is owned by a variety of retail and institutional investors. Top institutional investors include First Manhattan Co. (7.29%), BlackRock Inc. (3.93%), Vanguard Group Inc. (3.22%), Deerfield Management Company L.P. Series C (2.19%), AIGH Capital Management LLC (1.96%) and State Street Corp (1.24%). Company insiders that own Evolus stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Lauren P Silvernail, Medytox Inc, Rui Avelar and Vikram Malik.
View institutional ownership trends for Evolus.

EOLS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Federated Hermes Inc., Group One Trading L.P., Charles Schwab Investment Management Inc., Simplex Trading LLC, BlackRock Inc., Prudential Financial Inc., and Northern Trust Corp. Company insiders that have sold Evolus company stock in the last two years include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Lauren P Silvernail, Rui Avelar, and Vikram Malik.
View insider buying and selling activity for Evolus or view top insider-selling stocks.

EOLS stock was acquired by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, AIGH Capital Management LLC, First Manhattan Co., Essex Investment Management Co. LLC, EAM Investors LLC, Worth Venture Partners LLC, Invesco Ltd., and Monarch Partners Asset Management LLC.
View insider buying and selling activity for Evolus or or view top insider-buying stocks.

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EOLS stock can currently be purchased for approximately $11.65.

Evolus (NASDAQ:EOLS) has a market capitalization of $652.97 million and generates $99.67 million in revenue each year. The company earns $-46.81 million in net income (profit) each year or ($1.30) on an earnings per share basis.

Evolus employs 167 workers across the globe.

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for Evolus is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at [email protected].